

Zahi Touma

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/84761/zahi-touma-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

121
papers

3,452
citations

28
h-index

56
g-index

131
ext. papers

4,767
ext. citations

4.5
avg, IF

5.45
L-index

#	Paper	IF	Citations
121	COVID-19 hospitalizations, intensive care unit stays, ventilation and death among patients with immune mediated inflammatory diseases compared to controls.. <i>Journal of Rheumatology</i> , 2022 ,	4.1	3
120	Herpes zoster in SLE: prevalence, incidence and risk factors.. <i>Lupus Science and Medicine</i> , 2022 , 9,	4.6	1
119	Cognitive Function Trajectories in Association With the Depressive Symptoms Trajectories in Systemic Lupus Erythematosus Over Time. <i>Arthritis Care and Research</i> , 2021 , 73, 1436-1443	4.7	7
118	Validity and reliability of patient reported outcomes measurement information system computerized adaptive tests in systemic lupus erythematosus. <i>Lupus</i> , 2021 , 30, 2102-2113	2.6	
117	Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	3
116	Consideration of Fibromyalgia in the Assessment and Treatment of SLE. <i>Current Treatment Options in Rheumatology</i> , 2021 , 7, 182-193	1.3	
115	Endorsement of the domains of knee and hip osteoarthritis (OA) flare: A report from the OMERACT 2020 inaugural virtual consensus vote from the flares in OA working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 618-622	5.3	1
114	Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials. <i>Rheumatic Disease Clinics of North America</i> , 2021 , 47, 415-426	2.4	1
113	Exploring the Mental Health Needs of Persons With Autoimmune Diseases During the Coronavirus Disease 2019 Pandemic: A Proposed Framework for Future Research and Clinical Care. <i>ACR Open Rheumatology</i> , 2021 , 3, 25-33	3.5	0
112	Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 years. <i>Lupus</i> , 2021 , 30, 578-586	2.6	2
111	New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	6
110	The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021 , 23, 29	5.7	9
109	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
108	Comment on: Association between depression and anxiety with skin and musculoskeletal clinical phenotypes in systemic lupus erythematosus: reply. <i>Rheumatology</i> , 2021 , 60, e152-e153	3.9	
107	Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. <i>Arthritis Care and Research</i> , 2021 , 73, 1243-1249	4.7	5
106	Cognitive impairment in systemic lupus erythematosus is negatively related to social role participation and quality of life: A systematic review. <i>Lupus</i> , 2021 , 30, 1617-1630	2.6	1
105	Metrics and definitions used in the assessment of cognitive impairment in systemic lupus erythematosus: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 819-830	5.3	1

104	Response to: Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE" by Whittall Garcia. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	
103	Longitudinal relationships between cognitive domains and DEPRESSION and anxiety symptoms in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1186-1192	5.3	1
102	Filgotinib or Lanraplenib in Moderate to Severe Cutaneous Lupus Erythematosus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study. <i>Rheumatology</i> , 2021 ,	3.9	1
101	Neuropsychiatric Systemic Lupus Erythematosus in Older Adults: Diagnosis and Management.. <i>Drugs and Aging</i> , 2021 , 39, 129	4.7	0
100	Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus.. <i>Lupus</i> , 2021 , 9612033211062530	2.6	1
99	Effect of TNF-inhibitor therapy on spinal structural progression in ankylosing spondylitis patients: A systematic review and meta-analysis. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 728-743	2.3	6
98	Joint trajectories of disease activity, and physical and mental health-related quality of life in an inception lupus cohort. <i>Rheumatology</i> , 2020 , 59, 3032-3041	3.9	6
97	Association between depression and anxiety with skin and musculoskeletal clinical phenotypes in systemic lupus erythematosus. <i>Rheumatology</i> , 2020 , 59, 3211-3220	3.9	11
96	Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBServe Studies. <i>Rheumatology and Therapy</i> , 2020 , 7, 949-965	4.4	10
95	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1333-1339	2.4	16
94	Measures of Anxiety in Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2020 , 72 Suppl 10, 630-644	4.7	2
93	Measures of Cognition in Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2020 , 72 Suppl 10, 660-675	4.7	2
92	Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	16
91	Response to reviewer. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 821	5.3	
90	Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. <i>Rheumatology</i> , 2020 , 59, 90-98	3.9	21
89	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020 , 72, 1820-1826	4.7	16
88	Validity Evidence for the Use of Automated Neuropsychologic Assessment Metrics As a Screening Tool for Cognitive Impairment in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020 , 72, 1809-1819	4.7	9
87	Prevalence and metric of depression and anxiety in systemic lupus erythematosus: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 84-94	5.3	32

86	Systemic lupus erythematosus symptom clusters and their association with patient-reported outcomes and treatment: Analysis of real-world data. <i>Arthritis Care and Research</i> , 2020 ,	4.7	1
85	Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies. <i>Patient Related Outcome Measures</i> , 2019 , 10, 1-7	2.9	12
84	Assessment of the psychometric properties of patient-reported outcomes of depression and anxiety in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 260-266	5.3	23
83	Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ). <i>Journal of Rheumatology</i> , 2019 , 46, 1192-1197	4.1	15
82	Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. <i>Arthritis and Rheumatology</i> , 2019 , 71, 91-98	9.5	60
81	Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019 , 71, 822-828	4.7	25
80	Psoriatic Arthritis Sonographic Enthesitis Instruments: A Systematic Review of the Literature. <i>Journal of Rheumatology</i> , 2019 , 46, 43-56	4.1	10
79	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344
78	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1400-1412	9.5	488
77	The Assessment of Anxiety and Depression and its Associated Factors in SLE. <i>Current Rheumatology Reviews</i> , 2019 , 15, 90-98	1.6	14
76	Drs. Tayer-Shifman and Touma reply. <i>Journal of Rheumatology</i> , 2019 , 46, 653	4.1	2
75	Disease course patterns in systemic lupus erythematosus. <i>Lupus</i> , 2019 , 28, 114-122	2.6	23
74	Minimal Clinically Important Difference: A Review of Outcome Measure Score Interpretation. <i>Rheumatic Disease Clinics of North America</i> , 2018 , 44, 177-188	2.4	41
73	What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 240-253	5.3	34
72	A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. <i>Rheumatology</i> , 2018 , 57, 1370-1376	3.9	16
71	Comparison of the Sensitivity to Change of the 36-Item Short Form Health Survey and the Lupus Quality of Life Measure Using Various Definitions of Minimum Clinically Important Differences in Patients With Active Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018 , 70, 125-133	4.7	27
70	Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms. <i>PLoS ONE</i> , 2018 , 13, e0196117	3.7	25
69	Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome. <i>Journal of Rheumatology</i> , 2018 , 45, 1406-1410	4.1	19

68	Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 1448-1461	4.1	16
67	Novel biological therapeutic approaches to cutaneous lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 1041-1047	5.4	3
66	Subcutaneous belimumab in the treatment of systemic lupus erythematosus. <i>Immunotherapy</i> , 2018 , 10, 1163-1173	3.8	3
65	Monophasic Disease Course in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 1131-1135	4.1	6
64	Effect of complete or partial proteinuria recovery on long-term outcomes of lupus nephritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 557-564	5.3	3
63	Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. <i>Lancet, The</i> , 2018 , 392, 1330-1339	4.0	161
62	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 1426-1439	4.1	33
61	Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans. <i>Nature Immunology</i> , 2018 , 19, 571-582	19.1	80
60	Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies. <i>Arthritis Care and Research</i> , 2017 , 69, 67-74	4.7	113
59	Reply. <i>Arthritis Care and Research</i> , 2017 , 69, 457	4.7	
58	Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. <i>Arthritis Research and Therapy</i> , 2017 , 19, 31	5.7	9
57	Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSERVE Canada Study. <i>Rheumatology International</i> , 2017 , 37, 865-873	3.6	41
56	Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort. <i>BioMed Research International</i> , 2017 , 2017, 5312960	3	9
55	Comparison of Spot Urine Protein to Creatinine Ratio to 24-Hour Proteinuria to Identify Important Change Over Time in Proteinuria in Lupus. <i>Journal of Clinical Rheumatology</i> , 2017 , 23, 301-307	1.1	3
54	Performance of Screening Tests for Cognitive Impairment in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2017 , 44, 1583-1589	4.1	31
53	The Role of Patient-Reported Outcomes in Systemic Lupus Erythematosus. <i>Current Treatment Options in Rheumatology</i> , 2017 , 3, 308-321	1.3	11
52	Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. <i>Lupus</i> , 2017 , 26, 365-372	2.6	33
51	The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 46, 791-797	5.3	3

50	Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. <i>Lupus Science and Medicine</i> , 2017 , 4, e000239	4.6	60
49	Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1225-38	5.4	9
48	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16039	51.1	422
47	Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study. <i>Journal of Rheumatology</i> , 2016 , 43, 1057-62	4.1	4
46	Impact of pulmonary disease on patient-reported outcomes and patient-performed functional testing in systemic lupus erythematosus. <i>Lupus</i> , 2016 , 25, 1004-11	2.6	11
45	Utility of Urinary Protein-Creatinine Ratio and Protein Content in a 24-Hour Urine Collection in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2016 , 68, 1310-9	4.7	19
44	SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement. <i>Journal of Rheumatology</i> , 2015 , 42, 1401-5	4.1	5
43	DEVELOPING AN IPAD™ APPLICATION FOR DATA COLLECTION IN A RHEUMATOLOGY RESEARCH CLINIC. <i>International Journal of Technology Assessment in Health Care</i> , 2015 , 31, 99-102	1.8	3
42	Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015 , 17, 296	5.7	13
41	Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. <i>Journal of Rheumatology</i> , 2014 , 41, 688-97	4.1	57
40	OP0042 Do We Know How and When to Stop Immunosuppressants in Lupus Patients?. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 76-76	2.4	2
39	Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. <i>Drug Design, Development and Therapy</i> , 2014 , 8, 2303-10	4.4	8
38	Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2013 , 15, 380	4.9	32
37	Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 723-37	5.4	19
36	Outcome measures in systemic lupus erythematosus. <i>Indian Journal of Rheumatology</i> , 2013 , 8, S46-S53	0.5	7
35	Skin nontuberculous mycobacterial infection in systemic lupus erythematosus: an unusual skin infection mimicking lupus vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2013 , 42, 498-506	5.3	16
34	Development and assessment of users' satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website. <i>Journal of Rheumatology</i> , 2013 , 40, 34-9	4.1	10
33	Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. <i>Current Opinion in Rheumatology</i> , 2013 , 25, 164-70	5.3	7

32	Systemic lupus erythematosus disease activity index 2000 responder index-50 website. <i>Journal of Rheumatology</i> , 2013 , 40, 733	4.1	25
31	The assessment of disease activity in rheumatic diseases. <i>International Journal of Rheumatology</i> , 2013 , 2013, 275691	2	
30	Development, sensibility, and reliability of the Toronto Axial Spondyloarthritis Questionnaire in inflammatory bowel disease. <i>Journal of Rheumatology</i> , 2013 , 40, 1726-35	4.1	15
29	Does the change in season affect disease activity in patients with psoriatic arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1370-3	2.4	5
28	SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years. <i>Lupus</i> , 2012 , 21, 1305-11	2.6	21
27	Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. <i>Rheumatology</i> , 2012 , 51, 528-34	3.9	20
26	Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months. <i>Rheumatology</i> , 2012 , 51, 1814-9	3.9	31
25	Cross-cultural adaptation and validation of Behçet's disease quality of life questionnaire. <i>BMC Medical Research Methodology</i> , 2011 , 11, 52	4.7	13
24	Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. <i>Arthritis Care and Research</i> , 2011 , 63, 1440-7	4.7	23
23	Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. <i>Journal of Rheumatology</i> , 2011 , 38, 69-78	4.1	84
22	SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. <i>Lupus</i> , 2011 , 20, 67-70	2.6	65
21	Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity. <i>Journal of Rheumatology</i> , 2011 , 38, 868-73	4.1	24
20	Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. <i>Journal of Rheumatology</i> , 2011 , 38, 60-3	4.1	12
19	Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. <i>Journal of Rheumatology</i> , 2011 , 38, 2395-9	4.1	38
18	Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?. <i>Journal of Rheumatology</i> , 2011 , 38, 1898-905	4.1	56
17	Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. <i>Journal of Rheumatology</i> , 2011 , 38, 275-84	4.1	54
16	SLEDAI-2K for a 30-day window. <i>Lupus</i> , 2010 , 19, 49-51	2.6	55
15	TNF polymorphisms in patients with Behçet disease: a meta-analysis. <i>Archives of Medical Research</i> , 2010 , 41, 142-6	6.6	44

14	Successful treatment of cardiac involvement in dermatomyositis with rituximab. <i>Joint Bone Spine</i> , 2008 , 75, 334-7	2.9	42
13	Efficacité du rituximab dans le traitement d'une dermatomyosite avec atteinte cardiaque. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2008 , 75, 471-474	0.1	0
12	Oral bisphosphonates in treatment of transient osteoporosis. <i>Clinical Rheumatology</i> , 2008 , 27, 529-32	3.9	28
11	Family history of lymphoma and risk for solid tumors in patients with Sjogren's syndrome. <i>Rheumatology International</i> , 2007 , 28, 87-8	3.6	1
10	The use of TNF-alpha blockers in Cogan's syndrome. <i>Rheumatology International</i> , 2007 , 27, 995-6	3.6	23
9	Cardiac sarcoidosis responding to monotherapy with infliximab. <i>Clinical Rheumatology</i> , 2007 , 26, 2001-3	3.9	60
8	Longitudinal myelitis in patient with systemic lupus erythematosus, homozygous prothrombin G20210A and heterozygous MTHFR 677T. <i>Lupus</i> , 2007 , 16, 517-20	2.6	6
7	Topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis. <i>Future Rheumatology</i> , 2007 , 2, 163-175		1
6	Long-delayed onset of chest wall pain defining a patient with SAPHO syndrome. <i>Journal of Clinical Rheumatology</i> , 2007 , 13, 338-40	1.1	2
5	Endobronchial stenting for respiratory complications in relapsing chondritis. <i>Clinical Rheumatology</i> , 2007 , 26, 271-3	3.9	6
4	Successful treatment of Sjogren's syndrome with rituximab. <i>Scandinavian Journal of Rheumatology</i> , 2006 , 35, 323-5	1.9	17
3	Successful retreatment with infliximab in patients with prior severe infusion reactions. <i>Clinical Rheumatology</i> , 2006 , 25, 540-1	3.9	12
2	Response of deep cutaneous vasculitis to infliximab. <i>Journal of the American Academy of Dermatology</i> , 2005 , 53, 353-4	4.5	15
1	Fatal streptococcal toxic shock syndrome in a patient with rheumatoid arthritis treated with etanercept. <i>Rheumatology</i> , 2005 , 44, 1200-1	3.9	5